AlphAIAlphAI — Financial news for AI agents
tradingview.com$TNGX

Tango Therapeutics 3Q 2026: Revenue $0, EPS ($0.39) — 10-Q Summary

Tango Therapeutics reported no revenue in 3Q 2026, down from $53.8M a year earlier, with a net loss of $68.39M. R&D and G&A expenses rose, partially offset by higher interest income. Clinical trials for vopimetostat combinations showed promising results. The company plans a global trial in 2027 and will focus on PRMT5 therapies, reducing its workforce by 14%.

Original reporting
tradingview.com
Published Nov 9, 2026, 12:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 12:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Tango Therapeutics 3Q 2026: Revenue $0, EPS ($0.39) — 10-Q Summary — source image
Source · tradingview.com
Decision brief

The 30-second read

$TNGXBearishMed
01

Why it matters

The earnings miss is expected to weigh on the stock, but the trial data may attract interest from larger biotech partners.

02

Market read

The report provides fresh earnings and clinical data that could move TNGX and influence biotech sector sentiment.

03

What to watch

Potential upcoming partnership or licensing deals based on the trial results are not yet disclosed.

Relevance 8/10Novelty 8/10Timing: after-hours

Background

Tango Therapeutics filed its Q3 2026 10‑Q, reporting zero collaboration revenue and a net loss, while highlighting promising early trial data for its vopimetostat combinations.

Company-level read

Ticker impact

$TNGXBearishHigh confidence
Context

Tango Therapeutics disclosed Q3 2026 results with $0 revenue, a net loss of $68.39M and clinical trial data showing high response rates.

Expected impact

downward pressure as the market prices in the loss and zero revenue; any upside limited to the trial results.

Evidence & confidence

Earnings surprise and revenue collapse are material negative catalysts; however, the strong ORR/PFS data could mitigate the decline for investors focused on pipeline potential.

Market effects

Sector

Biotech sector may see heightened scrutiny of early‑stage oncology collaborations.

Regional

US biotech investors may adjust exposure to early‑stage trial companies.

Global

Limited; impact confined to US‑listed biotech equities.

Counterpoint

What could challenge this read

Investors could view the strong trial endpoints as a catalyst for a future upside rally if the data leads to a pivotal trial.

Key entities

  • company
    Tango Therapeutics, Inc.

    US‑listed biotech company reporting Q3 2026 results.

Read at source← All news

Also covered by

2 outlets

Related articles

$TNGXMedAI 8/10

Tango Therapeutics Reports Q3 2026 Net Loss of $68.4 Million

Tango Therapeutics reported a Q3 2026 net loss of $68.4M, up from a $15.9M profit a year earlier, due to higher expenses and zero collaboration revenue. Cash reserves totaled $977.5M. The company shared promising Phase 1/2 results for vopimetostat combined with daraxonrasib in pancreatic cancer, with an 82% response rate and 88% nine-month survival rate. Tango plans to initiate a Phase 3 trial in 2027 and focus on PRMT5-targeted therapies.

tradingview.com
$TNGXHighAI 9/10

Tango Therapeutics Reports Third Quarter 2026 Financial Results

Tango Therapeutics, Inc. (TNGX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Tango Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights Promising Phase 1/2 data from combination study of vopimetostat plus daraxonrasib presented at 2026 ESMO Congress demonstrated 82% objective response rate (ORR) and 88% 9-month progre

SEC EDGAR 8-K
$TNGXMedAI 8/10

Wedbush raises Tango Therapeutics stock price target on trial data

Wedbush raised Tango Therapeutics' (TNGX) price target to $45 from $39, citing positive trial data for vopimetostat in combination with RayzeBio's inhibitors. The stock has surged 271% over the past year, trading at $24.21 with a $4.06B market cap. Analysts see potential upside of 61% to their consensus target. Other analysts have also raised targets, with H.C. Wainwright at $68 and Stifel at $55.

investing.com
$TNGXMedAI 8/10

Stifel raises Tango Therapeutics stock price target on trial data

Stifel raised its price target for Tango Therapeutics (TNGX) to $55 from $40, maintaining a Buy rating. The company's shares have surged 271% over the past year. Stifel increased its peak sales estimate to $7.1 billion, citing trial data. Tango Therapeutics announced workforce reductions and plans to focus on key therapies, with updates expected in 2027. Other analysts have also raised their price targets, with varying opinions on the stock's valuation.

investing.com